Spondyloarthritis
2
Pipeline Programs
8
Companies
1
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 6 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs1
1
IxekizumabPhase 3Monoclonal Antibody1 trial
CLassification of Axial SpondyloarthritiS Inception CohortN/A
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Eli Lilly and CompanyIxekizumab
Clinical Trials (1)
Total enrollment: 316 patients across 1 trials
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
Start: Apr 2016Est. completion: May 2019316 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space